Gold Eased on New Vaccine News

Gold Eased on New Vaccine News

Gold prices eased Monday when AstraZeneca offered new vaccine news in the fight against COVID-19, overshadowing an earlier boost from a weaker dollar. U.S. gold futures slipped 0.6% lower to $1,861.40 on the announcement. AstraZenaca reports its vaccine could be around 90% effective.

Earlier on Monday, gold was holding around $1875 as the dollar tumbled to lows not seen since 2018 and fears of inflation from economic stimulus increased.

The dollar index had declined to the lowest level in two and a half years after statements from U.S. officials that vaccines for the coronavirus may begin as soon as three weeks for now. The news made riskier assets more attractive to investors.

But whether the rollout of the vaccines will hurt gold because of the yellow metal’s status as a haven asset during times of uncertainty is unclear because it also serves as a hedge against inflation, Bloomberg reported. Central banks are pouring huge amounts of stimulus into the global economy, and that could trigger an increase in consumer prices.

Front-month gold futures dropped 0.4% last week to settle at $1,878.20 an ounce on COMEX, though the February contract rose 0.6% Friday. Gold is up more than $350 — or 23% — so far this year as investors have flocked to gold because of uncertainty from the coronavirus pandemic and the economy. It slipped 0.8% in October, its third consecutive monthly decline. Currently, the December contract is $1,865.20 an ounce and the DG spot price is $1,868.00

Gold has found technical support near $1,875 an ounce, but if the dollar rallies, it could push the metal down to $1,800 to $1,790, Michael McCarthy, chief strategist at CMC Markets, told Reuters.

The first Americans could receive a vaccine in the second week of December, according to Moncef Slaoui, the head of the government’s efforts to develop the inoculations, told CNN. Pfizer submitted an application Friday to the U.S. Food and Drug Administration for emergency use authorization of its vaccine, and the vaccine advisory committee is scheduled to meet Dec. 10.

The virus known as COVID-19 has killed 1.39 million people worldwide and sickened 58.6 million. Almost 21% of the cases — and 19% of the deaths — are in the U.S. The country has more than 12.2 million cases, more than any other nation. Pandemic-related lockdowns have sent millions of Americans into unemployment and curbed economic growth around the world.

A slew of U.S. economic data will be released Wednesday ahead of the Thanksgiving Day holiday on Thursday, during which markets will be closed. The releases include jobless claims, third-quarter GDP, durable goods orders, new home sales, consumer sentiment and consumer spending and core inflation data.

Front-month silver futures fell 1.2% last week to settle at $24.49 an ounce on Comex. The March contract increased 1.4% Friday. The most active contract gained 0.6% in October. The December contract is currently at $24.125 an ounce and the DG spot price is $24.03.

Spot palladium lost 0.2% last week to $2,338.50 an ounce and gained 0.1% Friday. It dropped 4.5% in October. Spot platinum climbed 6.7% last week to $958.60 an ounce. It rose 0.7% in the Friday and fell 6% in October. Currently, the DG spot price for platinum is $953.00 an ounce and palladium is $2,356.30.


Disclaimer: This editorial has been prepared by Dillon Gage Metals for information and thought-provoking purposes only and does not purport to predict or forecast actual results. This editorial opinion is not to be construed as investment advice or as a recommendation regarding any particular security, commodity or course of action. Opinions expressed herein cannot be attributable to Dillon Gage. Reasonable people may disagree about the events discussed or opinions expressed herein. In the event any of the assumptions used herein do not come to fruition, results are likely to vary substantially. It is not a solicitation or advice to make any exchange in commodities, securities or other financial instruments. No part of this editorial may be reproduced in any manner, in whole or in part, without the prior written permission of Dillon Gage Metals. Dillon Gage Metals shall not have any liability for any damages of any kind whatsoever relating to this editorial. You should consult your advisers with respect to these areas. By posting this editorial, you acknowledge, understand and accept this disclaimer.